Cabot Undervalued Stocks Advisor Special Bulletin
One of our portfolio stocks moves is being retired and there is news on five more.
Read More
market investment Archives
Cabot Undervalued Stocks Advisor Special Bulletin
One of our portfolio stocks moves from Strong Buy to Hold.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
Three retail stocks reported earnings.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
A Spanish news outlet, Intereconomia.com, is reporting that biotech company Amgen (AMGN) is in talks to buy Alexion Pharmaceuticals (ALXN) for close to $200 per share.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
Four stocks in our portfolios reported earnings this week.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
Crista is changing the rating on two stocks and retiring another.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
Crista reports good earnings announcements in five portfolio stocks.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
Thus far, the 11 portfolio companies that delivered second-quarter results have all met or exceeded Wall Street’s consensus earnings estimates.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
Today’s news: One stock is now Retired from the Growth & Income Portfolio; and one stock joins the Buy Low Opportunities Portfolio as a Strong Buy.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
Three of our portfolio stocks reported second-quarter (2Q) results. Here's what you need to know.
Read More
Two Ways to Invest in Panama
One of the biggest emerging market booms is happening in Panama, which is quickly becoming the Singapore of Central America. Here's how to invest in it.
Read More
Leucadia (LUK)
Although first quarter was a challenge with lower trading revenues at its brokerage firm, the company said February and March numbers improved. And analysts are forecasting positive earnings of $0.13 per share for second quarter. As well, the company has a dividend yield 1.72%,...
Read More
Is Gilead Sciences (GILD) Overvalued or Undervalued?
GILD has soared from under 20 to over 120 over the past four years, thanks to mushrooming revenues from Sovaldi and Harvoni, the company’s hepatitis C drugs, revenues grew 52% from last year—and that was the slowest revenue growth rate in five quarters!. the...
Read More